197 related articles for article (PubMed ID: 21911485)
1. Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma.
Cloninger C; Bernath A; Bashir T; Holmes B; Artinian N; Ruegg T; Anderson L; Masri J; Lichtenstein A; Gera J
Mol Cancer Ther; 2011 Dec; 10(12):2244-56. PubMed ID: 21911485
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.
Holmes B; Lee J; Landon KA; Benavides-Serrato A; Bashir T; Jung ME; Lichtenstein A; Gera J
J Biol Chem; 2016 Jul; 291(27):14146-14159. PubMed ID: 27226604
[TBL] [Abstract][Full Text] [Related]
3. Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamycin complex 1 (mTORC1) inhibitor sensitivity.
Martin J; Masri J; Cloninger C; Holmes B; Artinian N; Funk A; Ruegg T; Anderson L; Bashir T; Bernath A; Lichtenstein A; Gera J
J Biol Chem; 2011 May; 286(18):16402-13. PubMed ID: 21454539
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.
Shi Y; Sharma A; Wu H; Lichtenstein A; Gera J
J Biol Chem; 2005 Mar; 280(12):10964-73. PubMed ID: 15634685
[TBL] [Abstract][Full Text] [Related]
5. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
6. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.
Frost P; Shi Y; Hoang B; Gera J; Lichtenstein A
Mol Cancer Ther; 2009 Jan; 8(1):83-93. PubMed ID: 19139116
[TBL] [Abstract][Full Text] [Related]
7. Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling.
Marderosian M; Sharma A; Funk AP; Vartanian R; Masri J; Jo OD; Gera JF
Oncogene; 2006 Oct; 25(47):6277-90. PubMed ID: 16702957
[TBL] [Abstract][Full Text] [Related]
8. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
9. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
[TBL] [Abstract][Full Text] [Related]
10. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
11. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
[TBL] [Abstract][Full Text] [Related]
13. A unifying model for mTORC1-mediated regulation of mRNA translation.
Thoreen CC; Chantranupong L; Keys HR; Wang T; Gray NS; Sabatini DM
Nature; 2012 May; 485(7396):109-13. PubMed ID: 22552098
[TBL] [Abstract][Full Text] [Related]
14. MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.
Shi Y; Frost P; Hoang B; Yang Y; Fukunaga R; Gera J; Lichtenstein A
Oncogene; 2013 Jan; 32(2):190-7. PubMed ID: 22370634
[TBL] [Abstract][Full Text] [Related]
15. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
16. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
17. MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas.
Grzmil M; Huber RM; Hess D; Frank S; Hynx D; Moncayo G; Klein D; Merlo A; Hemmings BA
J Clin Invest; 2014 Feb; 124(2):742-54. PubMed ID: 24401275
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
Fan QW; Weiss WA
Methods Mol Biol; 2012; 821():349-59. PubMed ID: 22125077
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.
Shi Y; Yang Y; Hoang B; Bardeleben C; Holmes B; Gera J; Lichtenstein A
Oncogene; 2016 Feb; 35(8):1015-24. PubMed ID: 25961916
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
